Exagen Inc. (XGN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Exagen Inc. on December 23, 2020. The filing details a material amendment to the Co-Promotion Agreement with Janssen Biotech, Inc. regarding the promotion of SIMPONI®.
Key Financial Metrics
The filing does not provide general financial statements, revenue, profit, cash flow, or debt metrics. It specifically outlines the following financial terms for the amended promotion agreement:
- Adjusted Baseline: Approximately 28,750 prescribed units per quarter for Q4 2020, Q1 2021, and Q2 2021.
- Q4 2020 Fee Structure: Minimum promotion fee of $0.3 million; capped at 5% above the adjusted baseline.
- Q1 & Q2 2021 Fee Structure: Minimum promotion fee of $0.3 million per quarter; capped at 10% above the adjusted baseline.
- Tiered Fee Rate: For Q1 and Q2 2021, fees range from $500 to $1,000 per prescription based on incremental units over the baseline.
Material Changes Versus Prior Period
The primary change is the adjustment of the predetermined average baseline for total prescribed units and the introduction of specific minimum fees and caps for the quarters ending December 31, 2020, March 31, 2021, and June 30, 2021. Beginning with the quarter ended September 30, 2021, the agreement reverts to the original terms with no minimum fee and no cap on baseline units.
Outlook, Risks, and Management Commentary
Term Extension: The Co-Promotion Agreement expires on December 31, 2021. Exagen may extend the term for an additional 12 months by providing 180 days' written notice. If extended, the 2022 baseline is subject to future negotiation.
Confidentiality: The full text of the Amendment will be filed as an exhibit to the Form 10-K for the year ending December 31, 2020, with portions redacted for confidentiality.
Investor Verification Checklist
- Verify the actual prescribed units of SIMPONI® for Q4 2020 to determine if the $0.3 million minimum fee was exceeded.
- Monitor the upcoming Form 10-K filing for the full, redacted text of the Amendment.
- Track whether Exagen provides the 180-day notice required to extend the agreement beyond December 31, 2021.
- Assess the impact of the reverted fee structure (no minimum/cap) starting Q3 2021 on future revenue projections.